The RAS-RAF-MEK-ERK signaling cascade is the most frequently affected signaling pathway in colorectal cancer. BRAFV600E mutations serve as a drug-treatable hotspot and KRAS mutations as a predictor of susceptibility to anti-epidermal growth factor receptor therapy. Concomitant non-V600E BRAF and KRAS mutations may coexist and are rarely reported in the literature. We report a patient of colorectal carcinoma with inguinal lymph node metastases harboring mutations at the KRAS and BRAF non-V600E mutation codon detected by next-generation sequencing with an emphasis on clinical, pathological, and therapeutic implications of the mutation and review of the literature.
JonesJCRenfroLAAl-ShamsiHO, et al.Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol. 2017;35(23):2624–2630.
2.
SchirripaMBiasonPLonardiS, et al.Class 1, 2 and 3 BRAF-mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization. Clin Cancer Res. 2019;25(13):3954–3961.
3.
MidthunLShaheenSDeischJSenthilMTsaiJHsuehC-T. Concomitant KRAS and BRAF mutations in colorectal cancer. J Gastrointest Oncol.2019;10(3):577–581.
4.
DeshwarAMargonisGAAndreatosN, et al.Double KRAS and BRAF mutations in surgically treated colorectal cancer liver metastases: an international, multi-institutional case series. Anticancer Res. 2018;38:2891–2895.
5.
De RoockWClaesBBernasconiD, et al.Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762.
6.
SahinIHKazmiSMYorioJTBhadkamkarNAKeeBKGarrettCR. Rare though not mutually exclusive: a report of three cases of concomitant KRAS and BRAF mutation and a review of the literature. J Cancer. 2013;4(4):320–322.
7.
OliveiraCVelhoSMoutinhoC, et al.KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007;26(1):158–163.
8.
VittalAMiddintiAKasi Loknath KumarA. Are all mutations the same? A rare case report of coexisting mutually exclusive KRAS and BRAF mutations in a patient with metastatic colon adenocarcinoma. Case Rep Oncol Med. 2017;2017:2321052.
9.
GuglielminiPFRossiMGrossoF, et al.Double KRAS and BRAF mutations in colorectal cancer in a single oncologic department series. J Clin Oncol. 2013;31(15_suppl):e14657.
10.
Van CutsemEKohneCHLangI, et al.Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–2019.
